Trial intelligence / Profile preview

Atamestane and Toremifene in Advanced Breast Cancer

NCT00267553Phase 3Terminated

Sponsor
Intarcia Therapeutics
Start
Nov 2005
Modality
Irreversible Covalent Inhibitors
Countries
4
01

Overview

A Phase 3 trial of atamestane in breast cancer, sponsored by Intarcia Therapeutics. Started Nov 2005; status: terminated.

02

Drugs

atamestane
03

Conditions

breast cancer

Beyond the preview

Go deeper on NCT00267553.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00267553.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call